22 March 2021 | News
Drug compound’s target therapeutic area include solid cancers and COVID-19
Image credit- shutterstock.com
Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19’s post-recovery complications, which include heart damage, diabetes and multi-system inflammatory syndrome in children (MIS-C).
Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced the M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells. This resulted in tumour suppression in animal studies. It also demonstrated consistent anti-cancer activity in 53 human patient-derived cancers tested ex vivo.
“Today’s cancer immunotherapy combinations can cost upwards of $200,000/year, but beneficial responses in patients happen at 15% chance-at-random. We developed 010DS-Zn as a widely applicable immunotherapy to significantly increase these odds. As of today, we are concerned about the 120 million and more people with COVID-19 infection history who may suffer from long term recovery complications. We have manufactured sufficient quantity of 010DS-Zn to be used for multiple collaborations, and we are looking for capable partners to work with us on further studies on 010DS-Zn’s effect on human tumours and COVID-19 complications,” said Dr Fred Chung, Chief Scientific Officer and Co-founder Xylonix.